Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | USP2 | O75604 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | ESRRB | O95718 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804442 | 0.93 | CYP3A4 (0.50) | CYP3A4CYP2C9ALDH1A1USP2CYP1A2 | |
| SCHEMBL21877081 | 0.87 | RORC (0.47) | CYP3A4ALDH1A1USP2HSD17B10CYP2C19 | |
| SCHEMBL21963775 | 0.87 | CYP11B2 (0.52) | CYP3A4CYP2C9ALDH1A1USP2CYP1A2 | |
| SCHEMBL23539079 | 0.86 | GPR119 (0.49) | CYP3A4CYP2C9ALDH1A1USP2CYP1A2 | |
| SCHEMBL30990690 | 0.86 | CYP3A4 (0.49) | CYP3A4CYP2C9ALDH1A1USP2CYP1A2 | |
| SCHEMBL22805048 | 0.84 | CYP3A4 (0.55) | CYP3A4CYP2C9ALDH1A1USP2CYP1A2 | |
| SCHEMBL30769248 | 0.83 | CYP11B2 (0.55) | CYP3A4CYP2C9ALDH1A1CYP1A2HIF1A | |
| SCHEMBL31276408 | 0.81 | NPSR1 (0.51) | CYP3A4CYP2C9ALDH1A1USP2CYP1A2 | |
| SCHEMBL22804382 | 0.81 | CYP3A4 (0.52) | CYP3A4CYP2C9ALDH1A1USP2CYP1A2 | |
| SCHEMBL25164880 | 0.81 | CYP3A4 (0.65) | CYP3A4CYP2C9ALDH1A1USP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-113993872-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-3986896-B1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993872-A | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | CYP3A4 3752/4885CYP2C9 1323/4885ALDH1A1 3894/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | CYP3A4 3802/4885CYP2C9 1498/4885ALDH1A1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.